May 2018 PMID 29801017

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Full text PDF Download social card

Mentions

Peak: 10 in Aug 2022

across 6 sources since May 2018

Extended reach

334,839

potential audience

Total likes

468

Video views

15,170

Mentions per month

May 2018 – Dec 2025

Where it's discussed

News17 articles
X / Twitter13 posts
YouTube2 videos
Instagram2 posts
Facebook1 posts
Blogs1 articles

AI synopsis

What people are saying

The overall sentiment leans toward disagreement with the publication’s recommendations, with discussions highlighting fears of unnecessary biopsies and harm, as seen in comments referring to the risks associated with PSA testing, and skepticism about a mass screening approach. The tone suggests concern and critical analysis, with some users sharing links and referencing official guidelines to support their viewpoints.

AgreementLow agreement

Most comments reflect skepticism or disagreement with the recommendations, emphasizing potential harms and questioning the value of PSA screening.

InterestModerate interest

The discussions show moderate interest, with users engaging by referencing the publication and sharing links, indicating curiosity about the topic.

EngagementModerate engagement

Comments include personal opinions, citations of studies, and sharing opinions on the risks and benefits, demonstrating active engagement.

ImpactNeutral impact

The discussions seem to influence perceptions but do not appear to cause immediate widespread change or policy shifts, indicating a moderate impact.

Abstract in brief

The USPSTF recommends individual decision-making about PSA screening for men aged 55-69 since it can reduce prostate cancer deaths but also carries risks like false positives and side effects from treatment such as incontinence and erectile dysfunction.
Screening may prevent some cases of advanced prostate cancer, especially in high-risk groups like African American men and those with a family history, but it also leads to overdiagnosis and unnecessary treatment.
Overall, the decision to screen should involve weighing the potential benefits of reducing mortality against the possible harms of false positives, overtreatment, and side effects, particularly considering age and risk factors.]

Read the full abstract

All mentions

Impact of Finasteride on Blood Tests and Hormonal Levels in Men

This video discusses the necessary blood work when taking finasteride, highlighting its effects on serum hormones and implications for male pattern baldness treatment.

Haircafe · Jan 15, 2025 15,140 views

Understanding PSA Test and Prostate Cancer Screening Guidelines

Son tiles el PSA TR para el cancer de prostata. Today we discuss prostate cancer screening and bust common myths, referencing recent guidelines on early detection and testing recommendations.

Medicina Sin Mitos · Oct 29, 2025 30 views

Hany Ragy

@Hragy · X

Wrong message! Read this https://t.co/X7UlWBM1HM https://t.co/n7dRcHlFq0

Nov 18, 2024 · 1 like · 80,681 followers View post →

Adilson Boson, Jr

@AdilsonBoson · X

@AlessandroLoio2 JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710 Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement: against PSA-based screening for prostate cancer in men 70 years and older; For 55-69y, decision should be individualized.

Nov 8, 2023 · 116 followers View post →